France · Delayed Price · Currency is EUR MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 893.48 million. The enterprise value is 880.57 million.
| Market Cap | 893.48M |
| Enterprise Value | 880.57M |
Important Dates
The next confirmed earnings date is Tuesday, December 8, 2026.
| Earnings Date | Dec 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 35.91 million shares outstanding. The number of shares has increased by 12.61% in one year.
| Current Share Class | 35.91M |
| Shares Outstanding | 35.91M |
| Shares Change (YoY) | +12.61% |
| Shares Change (QoQ) | +1.70% |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | 22.97% |
| Float | 32.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.80 |
| PB Ratio | 291.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 23.47.
| Current Ratio | 4.67 |
| Quick Ratio | 4.60 |
| Debt / Equity | 23.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.83 |
| Interest Coverage | -3.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -13.06% |
| Return on Invested Capital (ROIC) | -20.59% |
| Return on Capital Employed (ROCE) | -23.75% |
| Weighted Average Cost of Capital (WACC) | 9.36% |
| Revenue Per Employee | 172,177 |
| Profits Per Employee | -221,894 |
| Employee Count | 141 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -69,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.01% in the last 52 weeks. The beta is 0.98, so MedinCell's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +40.01% |
| 50-Day Moving Average | 25.98 |
| 200-Day Moving Average | 25.55 |
| Relative Strength Index (RSI) | 47.70 |
| Average Volume (20 Days) | 57,481 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 24.28 million and -31.29 million in losses. Loss per share was -0.94.
| Revenue | 24.28M |
| Gross Profit | 24.28M |
| Operating Income | -20.74M |
| Pretax Income | -31.36M |
| Net Income | -31.29M |
| EBITDA | -20.04M |
| EBIT | -20.74M |
| Loss Per Share | -0.94 |
Balance Sheet
The company has 84.82 million in cash and 71.92 million in debt, with a net cash position of 12.91 million or 0.36 per share.
| Cash & Cash Equivalents | 84.82M |
| Total Debt | 71.92M |
| Net Cash | 12.91M |
| Net Cash Per Share | 0.36 |
| Equity (Book Value) | 3.06M |
| Book Value Per Share | 0.09 |
| Working Capital | 76.02M |
Cash Flow
In the last 12 months, operating cash flow was -24.55 million and capital expenditures -815,000, giving a free cash flow of -25.37 million.
| Operating Cash Flow | -24.55M |
| Capital Expenditures | -815,000 |
| Depreciation & Amortization | 705,000 |
| Net Borrowing | -4.79M |
| Free Cash Flow | -25.37M |
| FCF Per Share | -0.71 |
Margins
Gross margin is 100.00%, with operating and profit margins of -85.44% and -128.88%.
| Gross Margin | 100.00% |
| Operating Margin | -85.44% |
| Pretax Margin | -129.16% |
| Profit Margin | -128.88% |
| EBITDA Margin | -82.54% |
| EBIT Margin | -85.44% |
| FCF Margin | n/a |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.61% |
| Shareholder Yield | -12.61% |
| Earnings Yield | -3.50% |
| FCF Yield | -2.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for MedinCell is 34.51, which is 38.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 34.51 |
| Price Target Difference | 38.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 59.50% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedinCell has an Altman Z-Score of 4.16 and a Piotroski F-Score of 2.
| Altman Z-Score | 4.16 |
| Piotroski F-Score | 2 |